| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8169 | Solcitinib（GLPG0778） Featured | Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. |
|
| DCAPI1388 | Suplatast tosylate | Suplatast tosylate |
|
| DC8024 | T-5224 Featured | T-5224 is a selective inhibitor of c-Fos/activator protein (AP)-1, attenuates lipopolysaccharide-induced liver injury in mice. |
|
| DC7304 | TAK 715 | TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. |
|
| DC8813 | TD-4208 Featured | TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration of action in preclinical models of bronchoconstriction. |
|
| DC7516 | TG100-115 Featured | TG100115 is a PI3Kγ/δ inhibitor with IC50 of 83 nM/235 nM, with little effect on PI3Kα/β. Phase 1/2. |
|
| DCAPI1449 | Tiotropium Bromide Featured | Tiotropium Bromide is a muscarinic acetylcholine receptor (mAChR M) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel. This stops signaling between neurons and leads to muscle relaxation. |
|
| DC8736 | Tofacitinib Featured | Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent versus JAK2 and JAK1. Phase 3. |
|
| DC5165 | Tofacitinib (CP-690550) Citrate Featured | Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent versus JAK2 and JAK1. Phase 3. |
|
| DC6400 | Tranilast (SB 252218) Featured | Tranilast (SB 252218) |
|
| DC8153 | Umeclidinium bromide Featured | Umeclidinium bromide(GSK573719A) is a muscarinic receptor antagonist which is useful in treatment of chronic obstructive pulmonary disease (COPD). |
|
| DC10431 | Upadacitinib Featured | Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM. |
|
| DC7777 | Valategrast (R411) | Valategrast (R411), a small molecule antagonist of α4β1 integrin, represents a potential therapy for asthma |
|
| DC10029 | Verinurad Featured | Verinurad is an urate transporter inhibitor with EC50 value of 0.05 μM.Verinurad is useful in the modulation of blood or serum uric acid levels, reducing serum uric acid levels in a human. |
|
| DC11844 | VTP-43742 | VTP-43742 (VTP43742) is a highly potent, selective, oral RORγt inverse agonist for the treatment of autoimmune disorders, including multiple sclerosis and psoriasis.. |
|
| DC1061 | VX-702 (VX702) Featured | VX-702 is a highly selective inhibitor of p38 MAPKα with IC50 of 4-20 nM. |
|
| DCAPI1015 | Zafirlukast(Accolate) | Zafirlukast(Accolate) |
|
| DC9490 | Zaurategrast | Zaurategrast(CDP-323) is an oral α4-integrin inhibitor. |
|
| DCAPI1551 | Tacalcitol Featured | Tacalcitol is a synthetic vitamin D3 analog. This compound has been shown to regulate calcium levels and induce nerve growth factor production in epidermal keratinocytes. Additionally, Tacalcitol has been noted to promotes normal bone development by regul |
|
| DC7028 | SB242235 Featured | SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM. |
|
| DC12355 | Ceralifimod (ONO-4641) | Ceralifimod is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC50s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively. |
|
| DC7694 | BAF312 (Siponimod) Featured | BAF312 is a potent and selective agonist of S1P with EC50 value of 0.39nM for S1P1 receptors and 0.98nM for S1P5 receptors, respectively |
|
